TCHF II has already allocated 60% of the $130 million corpus raised last year. It has concluded seven investments to date. The current TCHF II portfolio is strategically diversified across domestic and export pharmaceuticals, cancer care clinics, dialysis centers, integrated regional diagnostic chains, and digital healthcare.
